Literature DB >> 16172179

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.

Mary F Hebert1, Helen E Smith, Thomas C Marbury, Suzanne K Swan, William B Smith, Robert W Townsend, Donald Buell, James Keirns, Ihor Bekersky.   

Abstract

Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. The objectives of this study were to estimate the pharmacokinetic parameters and plasma protein binding of micafungin in volunteers with moderate hepatic dysfunction (n = 8), volunteers with creatinine clearance < 30 mL/min (n = 9), and matched controls (n = 8 and n = 9, respectively). Single-dose micafungin pharmacokinetics were estimated using noncompartmental techniques. There was a statistically lower area under the observed micafungin concentration-time curve (AUC) from time 0 to infinity for subjects with moderate hepatic dysfunction as compared to control subjects (97.5 +/- 19 microg.h/mL vs 125.9 +/- 26.4 microg.h/mL, P = .03), although there was no difference in micafungin weight-adjusted clearance (10.9 +/- 1.7 mL/h/kg vs 9.8 +/- 1.8 mL/h/kg, P = .2). The difference in area under the concentration-time curve may be explained by the differences in body weight between subjects and controls. Renal dysfunction did not alter micafungin pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16172179     DOI: 10.1177/0091270005279580

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  51 in total

1.  Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis.

Authors:  N Undre; P Stevenson; E Baraldi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-09-29       Impact factor: 2.441

Review 2.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

3.  Bronchopulmonary disposition of micafungin in healthy adult volunteers.

Authors:  Anthony M Nicasio; Pamela R Tessier; David P Nicolau; R Fredrick Knauft; John Russomanno; Eric Shore; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

Review 4.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

5.  Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Authors:  David R Andes; Daniel K Reynolds; Scott A Van Wart; Alexander J Lepak; Laura L Kovanda; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

6.  Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Authors:  Annie Lee; Brendan Prideaux; Matthew Zimmerman; Claire Carter; Stephen Barat; David Angulo; Véronique Dartois; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 7.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 8.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

9.  Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  K Yoshikawa; Y Nakazawa; Y Katsuyama; K Hirabayashi; S Saito; T Shigemura; M Tanaka; R Yanagisawa; K Sakashita; K Koike
Journal:  Infection       Date:  2014-02-25       Impact factor: 3.553

10.  Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles.

Authors:  Shuai Shi; Elizabeth S Dodds Ashley; Barbara D Alexander; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2009-02-03       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.